{
  "citations" : [
    {
      "id" : 7283333,
      "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "authors" : [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "crossReferences" : [
        {
          "id" : 769250885,
          "resource" : "PubMed",
          "resourceId" : "21412232",
          "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
          "version" : 0
        },
        {
          "id" : 1449247827,
          "resource" : "DOI",
          "resourceId" : "10.1038/clpt.2011.34",
          "_url" : "http://dx.doi.org/10.1038%2Fclpt.2011.34",
          "version" : 0
        }
      ],
      "day" : -1,
      "hasKeyword" : true,
      "journal" : "Clinical pharmacology and therapeutics",
      "meshTerms" : [
        "Animals",
        "Aryl Hydrocarbon Hydroxylases",
        "Cytochrome P-450 CYP2C9",
        "Drug Administration Schedule",
        "Drug-Related Side Effects and Adverse Reactions",
        "Humans",
        "Pharmaceutical Preparations",
        "Pharmacogenetics",
        "Practice Guidelines as Topic"
      ],
      "month" : 5,
      "nonHuman" : false,
      "objCls" : "Literature",
      "page" : "662-73",
      "pediatric" : false,
      "pgkbPublication" : false,
      "pubDate" : "2011-05-01T00:00:00-07:00",
      "pubmedMeshTerms" : [],
      "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
      "terms" : [],
      "type" : "Literature",
      "version" : 4,
      "volume" : "89",
      "year" : 2011
    }
  ],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166104992",
    "name" : "Annotation of DPWG Guideline for zuclopenthixol and CYP2D6",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : true,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1183704549,
        "date" : "2011-08-10T00:00:00-07:00",
        "type" : "Create",
        "version" : 0
      },
      {
        "id" : 1450415070,
        "date" : "2019-05-23T16:10:30.991-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450820674,
        "date" : "2019-10-03T16:15:50.560-07:00",
        "description" : "No changes based on August 2019 guidelines",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450956540,
        "date" : "2020-01-31T14:22:54.411-08:00",
        "description" : "Updated link to 2011 DPWG methods",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450963982,
        "date" : "2020-02-11T08:51:48.421-08:00",
        "description" : "Fixed links to 2018 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451431288,
        "date" : "2021-05-04T00:00:00-07:00",
        "description" : "Added extended dosing",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451701060,
        "date" : "2022-03-02T15:02:02.360-08:00",
        "description" : "Added May 2021 update to recommendations",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704236,
        "date" : "2022-03-03T16:33:32.793-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451707881,
        "date" : "2022-03-08T13:10:32.829-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451723420,
        "date" : "2022-03-18T11:27:52.660-07:00",
        "description" : "Updated annotation based on February 2022 release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732876,
        "date" : "2022-03-28T09:57:46.690-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451741510,
        "date" : "2022-04-05T11:21:57.300-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451884800,
        "date" : "2022-09-16T14:52:38.265-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452057785,
        "date" : "2023-04-03T16:04:04.305-07:00",
        "description" : "aded DPWG guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146540,
        "date" : "2023-07-03T13:40:15.288-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452408281,
        "date" : "2024-03-14T08:02:29.524-07:00",
        "description" : "Updated links for risk analysis pdf.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15142974,"title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923774","crossReferences":[{"id":1452412000,"resource":"PubMed Central","resourceId":"PMC10923774","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923774"},{"id":1452056756,"resource":"PubMed","resourceId":"37002327","_url":"https://www.ncbi.nlm.nih.gov/pubmed/37002327"},{"id":1452056757,"resource":"DOI","resourceId":"10.1038/s41431-023-01347-3","_url":"http://dx.doi.org/10.1038%2Fs41431-023-01347-3"}],"objCls":"Literature","pubDate":"2024-03-01T00:00:00-08:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"},
      {"id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature","pubDate":"2011-05-01T00:00:00-07:00","terms":[],"type":"Literature"},
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA452629",
        "name" : "zuclopenthixol",
        "version" : 6
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1447982014,
      "html" : "<p>For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose. For ultrarapid metabolizers, if the effectiveness is insufficient a dose increase not exceeding 1.5x normal dose is suggested.</p>\n",
      "version" : 2
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1447982013,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-between-cyp2d6-cyp3a4-and-cyp1a2-and-antipsychotics-european-journal-of-human-genetics-2023\">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.  European journal of human genetics (2023)</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines for zuclopenthixol and CYP2D6 as per the February 2022 guidelines and further details on the assessed literature [Article:<a href=\"/pmid/37002327\">37002327</a>]. Wording in the poor, intermediate, and ultrarapid metabolizer recommendation changed from &quot;standard&quot; to &quot;normal&quot; and is reflected in the table below.</p>\n<h3 id=\"february-2022-update\">February 2022 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has updated their therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotype. An alternate drug is no longer recommended for ultrarapid metabolizer (UM) patients and the guideline notes the relative lack of evidence available to guide dose changes for UM patients.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_February_2022_guidelines.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_February_2022_guidelines.pdf\">Dutch guidelines February 2022 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>zuclopenthixol</td>\n<td>The risk of ineffectiveness may be elevated. The genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration</td>\n<td>There is insufficient information available to make a dosage recommendation. - if the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>zuclopenthixol</td>\n<td>The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher.</td>\n<td>Use 75% of the normal dose.</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>zuclopenthixol</td>\n<td>The risk of side effects may be elevated. The genetic variation results in a decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.6-fold higher.</td>\n<td>Use with 50% of the normal dose.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_CYP2D6_zuclopenthixol_1547-1548-1549.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_CYP2D6_zuclopenthixol_1547-1548-1549.pdf\">Read for more information about this recommendation</a>, <a download=\"CYP2D6.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CYP2D6.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_CYP2D6_zuclopenthixol_1547-1548-1549.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_CYP2D6_zuclopenthixol_1547-1548-1549.pdf\">DPWG risk analysis document</a> for zuclopenthixol and CYP2D6:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting zuclopenthixol to be potentially beneficial for the prevention of side effects and for effectiveness. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the KNMP Pharmacogenetics Working Group recommends adhering to the gene-drug guideline.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"may-2021-update\">May 2021 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has updated their therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotype. They now recommend a dose reduction for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). They also recommend a dose increase or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 ultrarapid metabolizers (UMs).</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_May_2021.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_May_2021.pdf\">Dutch guidelines May 2021 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>zuclopenthixol</td>\n<td>The risk of ineffectiveness may be elevated. The genetic variation leads to an increased conversion of zuclopentixol, which causes the plasma concentration to be approximately 33% lower.</td>\n<td>Use 1.5 times the standard dose or choose an alternative.<br/>Antipsychotics that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>zuclopenthixol</td>\n<td>The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher.</td>\n<td>Use 75% of the standard dose.</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>zuclopenthixol</td>\n<td>The risk of side effects may be elevated. The genetic variation results in a decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.7-fold higher.</td>\n<td>Use with 50% of the standard dose.</td>\n</tr>\n</tbody>\n</table>\n<h4 id=\"preemptive-genotyping-1\">Preemptive genotyping</h4>\n<p>Excerpts from the DPWG risk analysis document for zuclopenthixol and CYP2D6:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting zuclopenthixol to be potentially beneficial for the prevention of side effects and for effectiveness. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the KNMP Pharmacogenetics Working Group recommends adhering to the gene-drug guideline.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotype. They recommend a dose reduction or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). They also recommend a dose increase or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 ultrarapid metabolizers (UMs) who have low zuclopenthixol plasma concentrations.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>zuclopenthixol</td>\n<td>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased zuclopentixol plasma concentrations.</td>\n<td>No data have been published from studies into the pharmacokinetics and effects of zuclopentixol for this phenotype.<br/>As a precaution, the prescriber should advised to be alert to a decreased zuclopentixol plasma concentration and - if necessary - the dose should be increased on the basis of the clinical effect, or an alternative should be prescribed according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>zuclopenthixol</td>\n<td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.</td>\n<td>Advise the prescriber to start with 75% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>zuclopenthixol</td>\n<td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.</td>\n<td>Advise the prescriber to start with 50% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td>\n</tr>\n</tbody>\n</table>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotypes [Article:<a href=\"/pmid/21412232\">21412232</a>].  For PM genotypes, they recommend reducing dose by 50% or selecting an alternative drug.  For IM genotypes, they recommend reducing dose by 25% or selecting an alternative drug.  For UM genotypes, they state that there are insufficient data to allow calculation of dose adjustment, and to be alert to low zuclopenthixol plasma concentrations or to select an alternative drug.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype (Genotype)</th>\n<th>Therapeutic Dose Recommendation</th>\n<th>Level of Evidence</th>\n<th>Clinical Relevance</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td>\n<td>Reduce dose by 50% or select alternative drug (e.g., flupenthixol, quetiapine, olanzapine, clozapine).</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5.  Kinetic effect (S).</td>\n</tr>\n<tr>\n<td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td>\n<td>Reduce dose by 25% or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (S).</td>\n</tr>\n<tr>\n<td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td>\n<td>Insufficient data to allow calculation of dose adjustment. Be alert to low zuclopenthixol plasma concentrations or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).</td>\n<td>not given.</td>\n<td>not given.</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods</a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good quality.&quot;</li>\n<li>S: statistically significant difference.</li>\n<li>Please see attached PDF for detailed information about the evaluated studies: <a download=\"zuclopenthixol_CYP2D6_271111.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/zuclopenthixol_CYP2D6_271111.pdf\">Zuclopenthixol CYP2D6 </a></li>\n</ul>\n",
      "version" : 18
    },
    "version" : 36
  }
}